市場調查報告書
商品編碼
1471261
智慧胰島素筆和幫浦市場:按產品、可用性、應用和最終用途 - 2024-2030 年全球預測Smart Insulin Pens & Pumps Market by Product (Smart Insulin Pens, Smart Insulin Pumps), Usability (Prefilled, Reusable), Application, End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年智慧胰島素筆和幫浦市場規模為13.8億美元,預計2024年將達15.1億美元,2030年將達26.8億美元,複合年成長率為9.89%。
智慧胰島素筆和幫浦包括糖尿病管理中使用的設備,可實現胰島素管理自動化並增強對血糖值的控制。智慧胰島素筆是先進的設備,旨在更準確、更方便、更整合地輸送胰島素。這些筆提供劑量追蹤、記錄最後一次劑量的時間和劑量的記憶功能以及與數位健康應用程式連接以監測一段時間內的血糖濃度和胰島素劑量等功能。另一方面,智慧胰島素幫浦是一種複雜的設備,透過放置在皮下的導管每天 24 小時連續輸送短效或速效胰島素。智慧胰島素幫浦與連續血糖監測 (CGM) 系統整合,可根據血糖水平調整即時胰島素輸送。全球糖尿病診斷數量的不斷增加以及老年人口對居家照護環境的日益偏好正在推動對有效管理解決方案的需求。然而,高昂的初始成本、經常性費用以及對產品召回的擔憂限制了許多患者的使用並阻礙了市場成長。也就是說,提供與行動應用程式和雲端儲存連接的智慧胰島素設備的技術進步,以及微創或非侵入性胰島素輸送方法的開發,預計將為智慧胰島素筆和胰島素幫浦市場帶來潛在機會。創建。
主要市場統計 | |
---|---|
基準年[2023] | 13.8億美元 |
預測年份 [2024] | 15.1億美元 |
預測年份 [2030] | 26.8億美元 |
複合年成長率(%) | 9.89% |
支援藍牙的智慧胰島素筆的產品採用激增,以支持胰島素治療的更深入追蹤和管理
第一代智慧型胰島素筆能夠自動記錄胰島素注射的時間、日期和數量,提供基本資料追蹤。這些設備旨在透過簡化追蹤過程來提高使用者對其胰島素治療方案的依從性。第二代智慧胰島素筆建立在前身產品的基礎上,融入了更先進的功能,例如劑量計算器,可以根據與飲食和血糖值。許多這些設備還具有儲存功能,可以全面儲存胰島素給藥歷史。支援藍牙的智慧胰島素筆是胰島素輸送技術的重大進步。這些設備可以無線連接到智慧型手機和其他智慧型設備,從而將劑量資料傳輸到專用應用程式。這種連接支持更詳細的胰島素治療追蹤和管理,有可能實現更好的血糖控制。 USB連接的智慧型胰島素筆透過USB介面將筆連接到電腦,直接傳輸劑量資訊。此功能允許將胰島素劑量資料輕鬆上傳到管理軟體以進行審查、追蹤和規劃,從而提供易於理解的糖尿病管理方法。智慧胰島素幫浦是先進的設備,可提供連續皮下胰島素輸注 (CSII) 以控制血糖值。這些設備在基礎和Bolus胰島素給藥方面提供高度客製化,並且許多設備具有整合連續血糖監測儀 (CGM) 和演算法驅動的劑量調整等功能。智慧胰島素幫浦旨在密切模仿您身體的自然胰島素分泌,提供更準確的血糖控制。智慧型手機整合和遠端監控功能等先進的連接功能支援即時調整、增強的資料追蹤和改善糖尿病管理中的患者治療效果。
最終用途:擴大智慧胰島素筆和幫浦在醫院和診所的使用
由於對以患者為中心的醫療保健解決方案的需求不斷成長,居家照護佔據了智慧胰島素筆和胰島素幫浦市場的很大一部分。這些設備方便、易用,使患者能夠在舒適的家中更有效、更仔細地管理糖尿病。將智慧技術整合到這些設備中,透過提醒、劑量追蹤以及與醫療保健提供者遠端共用資料的能力,進一步增強了對藥物治療方案的依從性。醫院和診所正在利用智慧胰島素筆和幫浦來加強住院和門診病人糖尿病患者的照護。這些設施受益於智慧型設備提供的準確且簡便的給藥方式,有助於更好的血糖值控制和患者治療結果。此外,這些智慧型設備收集的資料可以整合到患者健康記錄中,從而促進醫療保健專業人員採用整體方法進行糖尿病管理和治療協調。該研究所透過進行研究和開發來改進技術,在智慧胰島素筆和幫浦生態系統中發揮重要作用。這包括測試和檢驗新功能、確保設備準確性以及創新資料分析功能。從此類活動中獲得的見解將有助於提高智慧胰島素管理設備的可用性和有效性,最終透過改進的糖尿病控制和管理策略使最終用戶受益。
區域洞察
由於美洲糖尿病盛行率高、醫療基礎設施強大以及對先進糖尿病管理解決方案的認知,美洲成為智慧胰島素筆和胰島素幫浦的重要市場。在美洲,技術創新以及人工智慧和物聯網與醫療保健設備的整合正在推動智慧胰島素設備的使用。此外,美國市場受到政府對醫療保健創新的支持和對糖尿病護理設備的補貼的推動,消費者往往更喜歡更容易使用、侵入性較小的設備。歐洲、中東和非洲地區表現出多樣化的消費者需求和購買行為,受到不同醫療保健政策、經濟力量和意識層級的影響。歐盟 (EU) 非常注重醫療保健技術和以患者為中心的護理,許多國家都為智慧胰島素設備提供補償。因此,德國、法國和英國等國先進胰島素輸送系統的普及相對較高。在醫療保健支出增加和糖尿病管理意識增強的推動下,智慧胰島素設備的採用正在中東地區擴大。由於衛生基礎設施有限和收入水平參差不齊,非洲面臨獨特的挑戰。然而,人們對經濟高效且易於使用的胰島素筆和幫浦越來越感興趣,特別是在都市區。亞太地區的特徵是市場潛力巨大,人口眾多,醫療基礎建設完善,糖尿病盛行率不斷上升。此外,消費者高度接受創新的糖尿病管理設備,公司正大力投資研發以滿足國內和全球需求。
FPNV定位矩陣
FPNV定位矩陣對於評估智慧胰島素筆和幫浦市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對智慧胰島素筆和幫浦市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 智慧胰島素筆和幫浦市場的市場規模和預測是多少?
2.在智慧胰島素筆和幫浦市場的預測期內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.智慧胰島素筆和幫浦市場的技術趨勢和法規結構是什麼?
4.智慧胰島素筆和幫浦市場主要供應商的市場佔有率是多少?
5. 進入智慧胰島素筆和幫浦市場的合適型態和策略手段是什麼?
[198 Pages Report] The Smart Insulin Pens & Pumps Market size was estimated at USD 1.38 billion in 2023 and expected to reach USD 1.51 billion in 2024, at a CAGR 9.89% to reach USD 2.68 billion by 2030.
Smart insulin pens and pumps encompass devices utilized in diabetes management to automate insulin delivery, enhancing the control of blood glucose levels. Smart insulin pens are advanced devices designed to administer insulin with enhanced precision, convenience, and integration. These pens offer features such as dose tracking, memory functions to log the time and amount of the last dose, and the ability to connect with digital health applications to monitor glucose levels and insulin administration over time. Smart insulin pumps, on the other hand, are sophisticated devices that continuously deliver short or rapid-acting insulin 24 hours a per day via a catheter placed under the skin. Smart insulin pumps integrate with continuous glucose monitoring (CGM) systems to adjust real-time insulin delivery based on glucose levels. A global rise in diabetes diagnoses and a Rising preference for homecare settings among the geriatric populace drive demand for effective management solutions. However, high initial costs and recurring expenses with concern over product recall can limit accessibility for many patients, hindering market growth. Nevertheless, technological advancements in smart insulin devices offering connectivity with mobile applications and cloud storage and developing minimally invasive or non-invasive insulin delivery methods are expected to create potential opportunities for the smart insulin pens and pumps market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.38 billion |
Estimated Year [2024] | USD 1.51 billion |
Forecast Year [2030] | USD 2.68 billion |
CAGR (%) | 9.89% |
Product: Burgeoning adoption of bluetooth-enabled smart insulin pens supports more detailed tracking and management of one's insulin therapy
The first generation of smart insulin pens is characterized by their ability to automatically record the time, date, and amount of insulin injected, offering a basic level of data tracking. These devices aim to enhance the user's adherence to their insulin regimen by simplifying the tracking process. Second-generation smart insulin pens build upon the foundation laid by their predecessors by incorporating more advanced features such as dose calculators, which recommend insulin dosages based on user input related to meals and blood glucose levels. Many of these devices also feature memory functions that comprehensively store insulin dosing history. Bluetooth-enabled smart insulin pens represent a significant advancement in insulin delivery technology. These devices can connect wirelessly to smartphones or other smart devices, enabling the transfer of dosing data to dedicated applications. This connectivity supports more detailed tracking and management of insulin therapy, potentially leading to better glycemic control. USB-connected smart insulin pens directly transfer dosing information by connecting the pen to a computer via a USB interface. This feature allows for the easy upload of insulin administration data to management software for review, tracking, and planning purposes, providing a straightforward approach to diabetes management. Smart insulin pumps are advanced devices that deliver continuous subcutaneous insulin infusion (CSII) to manage blood glucose levels. These devices offer a high level of customization in basal and bolus insulin delivery, and many are now equipped with features such as integrated continuous glucose monitors (CGMs) and algorithm-driven dosing adjustments. Smart insulin pumps are designed to closely mimic the body's natural insulin release closely, offering more precise glucose control. Advanced connectivity features, including smartphone integration and remote monitoring capability, support real-time adjustments, enhanced data tracking, and improved patient outcomes in diabetes management.
End-Use: Evolving usage of smart insulin pens and pumps in hospitals and clinics
Homecare represents a significant portion of the smart insulin pens and pumps market, driven by the increasing demand for patient-centric healthcare solutions. These devices deliver convenience, ease of use, and the capability for patients to manage their diabetes more effectively and discretely from the comfort of their homes. Integrating smart technology in these devices further enhances adherence to medication regimens through reminders, dose tracking, and the capability to share data with healthcare providers remotely. Hospitals and clinics utilize smart insulin pens and pumps to provide enhanced care for inpatients and outpatients with diabetes. These institutions benefit from the precision and ease of dose administration offered by smart devices, contributing to better blood glucose level management and patient outcomes. Moreover, the data collected by these smart devices can be integrated into the patient's health record, facilitating a comprehensive approach to diabetes management and treatment adjustments by healthcare professionals. Laboratories play a crucial role in the smart insulin pens and pumps ecosystem by conducting research and development to improve the technology. This includes testing and validating new features, ensuring device accuracy, and innovating on data analytics capabilities. The insights from these activities help enhance the usability and effectiveness of smart insulin management devices, ultimately benefiting the end-users through improved diabetes control and management strategies.
Regional Insights
The Americas represent a significant market for smart insulin pens and pumps owing to the high prevalence of diabetes, robust healthcare infrastructure, and high awareness regarding advanced diabetes management solutions. In the Americas, technological innovations and the integration of AI and IoT into healthcare devices have propelled the usage of smart insulin devices. Furthermore, the American market is driven by governmental support for healthcare innovations and subsidies for diabetes care devices, with consumers showing a preference for user-friendly, minimally invasive devices. EMEA region showcases varied consumer needs and purchasing behaviors influenced by diverse healthcare policies, economic capabilities, and awareness levels. The European Union strongly focuses on healthcare technology and patient-centric care, with many countries reimbursing smart insulin devices. This has resulted in a relatively high penetration of advanced insulin delivery systems in countries such as Germany, France, and the UK. The Middle East is witnessing growth in the adoption of smart insulin devices, aided by increasing healthcare expenditure and rising awareness about diabetes management. Africa faces unique challenges due to its limited healthcare infrastructure and varying income levels. However, there is a growing interest in cost-effective and easy-to-use insulin pens and pumps, especially in urban areas. The Asia-Pacific region is characterized by its vast market potential, driven by a large population base, improving healthcare infrastructure, and increasing prevalence of diabetes. Furthermore, consumers have a high acceptance of innovative diabetes management devices, with companies investing heavily in R&D to meet domestic and global demand.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Smart Insulin Pens & Pumps Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Smart Insulin Pens & Pumps Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Smart Insulin Pens & Pumps Market, highlighting leading vendors and their innovative profiles. These include B. Braun Melsungen AG, Becton, Dickinson and Company, Bigfoot Biomedical, Inc., Biocon Ltd., Debiotech SA, Eli Lilly and Company, Emperra GmbH, F. Hoffmann-La Roche Ltd., Haselmeier GmbH, Insulet Corporation, Johnson & Johnson Services Inc., Medtronic PLC, Medtrum Technologies Inc., NIPRO EUROPE GROUP COMPANIES, Novo Nordisk A/S, Owen Mumford Limited, pendiq GmbH, Sanofi S.A., SOOIL Development Co., Ltd., Tandem Diabetes Care, Inc., Terumo Group, Wockhardt Limited, and Ypsomed Holding.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Smart Insulin Pens & Pumps Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Smart Insulin Pens & Pumps Market?
3. What are the technology trends and regulatory frameworks in the Smart Insulin Pens & Pumps Market?
4. What is the market share of the leading vendors in the Smart Insulin Pens & Pumps Market?
5. Which modes and strategic moves are suitable for entering the Smart Insulin Pens & Pumps Market?